Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

The company's OCS technology offers dynamic solutions that support heart transplants beyond the capabilities of static cold storage, giving TransMedics a competitive edge in the higher acuity end ...

TransMedics currently holds a dominant share of the overall Donation after Circulatory Death (DCD) market, which positions the company well for future growth as DCD volumes increase. The company's OCS ...

A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website ... for the treatment of end-stage heart, lung, and liver failure.

TransMedics holds a significant market share in heart, lung, and liver transplants, with its OCS technology offering a superior alternative to traditional static cold storage methods. The company ...

TransMedics holds a significant market share in heart, lung, and liver transplants, with its OCS technology offering a superior alternative to traditional static cold storage methods. The company's ...

Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on ...

Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on ...

TransMedics is a top dog and first mover in an important industry, but it sold off heavily after earnings. Despite the sell-off, the company has numerous growth drivers that make it compelling ...